These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 6390124

  • 21. [Circulating immune complexes and insulin-binding capacity of the serum of diabetics].
    Vel'bri SK, Lilleorg AL, Kerge IaKh.
    Probl Endokrinol (Mosk); 1986; 32(2):25-8. PubMed ID: 3520540
    [Abstract] [Full Text] [Related]

  • 22. [Comparative multicenter study of bovine insulin with forms more purified of swine and human insulin in the treatment of type 1 diabetes mellitus].
    Russo EM, Wajchenberg BL, Romaldini JH, Liberman B, Gross JL, Reis LC.
    AMB Rev Assoc Med Bras; 1991; 37(2):73-8. PubMed ID: 1658875
    [Abstract] [Full Text] [Related]

  • 23. [Semisynthetic human insulin in the treatment of diabetes type I. Preliminary experience].
    Vitacolonna E, Consoli A, Capani F.
    Boll Soc Ital Biol Sper; 1984 Oct 30; 60(10):1849-52. PubMed ID: 6394033
    [Abstract] [Full Text] [Related]

  • 24. Does insulin administration contribute to immune complex formation in diabetes?
    Campbell LV, Charlesworth JA, Pasterfield GV, Jenkins A, Pussell BA.
    Clin Exp Immunol; 1984 Nov 30; 58(2):255-63. PubMed ID: 6388921
    [Abstract] [Full Text] [Related]

  • 25. Human anti-insulin antibodies.
    Faulk WP, Karam JH, Fudenberg HH.
    J Immunol; 1971 Apr 30; 106(4):1112-6. PubMed ID: 5102837
    [No Abstract] [Full Text] [Related]

  • 26. Insulin deposits in membranous nephropathy associated with diabetes mellitus.
    Furuta T, Seino J, Saito T, Sato H, Agatsuma J, Ootaka T, Satoh T, Yoshinaga K.
    Clin Nephrol; 1992 Feb 30; 37(2):65-9. PubMed ID: 1551252
    [Abstract] [Full Text] [Related]

  • 27. [Insulin antibodies and the actual insulin requirements in children and adolescents with primary diabetes].
    Karczewska K, Feluś E, Panek G, Otto-Buczkowska E, Dudziak Z.
    Med Dosw Mikrobiol; 1974 Feb 30; 26(4):325-30. PubMed ID: 4475336
    [No Abstract] [Full Text] [Related]

  • 28. [Medium-term results of treatment with biosynthetic human insulin in diabetic children already in therapy with insulin of animal origin].
    Vanelli M, Bolondi O, Boselli E, Chiari G, Vittorangeli R, Rasori E, Nori G, Bernasconi S.
    Minerva Pediatr; 1987 Aug 31; 39(15-16):669-74. PubMed ID: 3312993
    [No Abstract] [Full Text] [Related]

  • 29. [The place of "monocomponent" insulins in diabetes mellitus therapy].
    Teuscher A.
    Schweiz Med Wochenschr; 1975 Apr 19; 105(16):485-94. PubMed ID: 1215860
    [Abstract] [Full Text] [Related]

  • 30. [Effect of monocomponent insulin serum anti-insulin antibody levels (author's transl)].
    García de los Ríos M, Mella I, Durruty P, Ruiz F, López G, Tapia JC, González G.
    Rev Med Chil; 1981 Jun 19; 109(6):509-15. PubMed ID: 7036310
    [No Abstract] [Full Text] [Related]

  • 31. [Preliminary note on anti-insulin antibody formation in diabetics treated with porcine insulin].
    Bchir F, Boujaafar N, Ben Salem M, Achour A.
    Arch Inst Pasteur Tunis; 1984 Mar 19; 61(1):1-8. PubMed ID: 6398991
    [Abstract] [Full Text] [Related]

  • 32. [Treatment of allergy to monocomponent porcine and bovine insulin with monocomponent human insulin].
    Bruni B, Campana M, Carlini M, Gamba Ansaldi S, Grassi G, Regis G, Turco GL.
    Minerva Endocrinol; 1984 Mar 19; 9(2):173-9. PubMed ID: 6390132
    [No Abstract] [Full Text] [Related]

  • 33. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals.
    Schernthaner G, Borkenstein M, Fink M, Mayr WR, Menzel J, Schober E.
    Diabetes Care; 1983 Mar 19; 6 Suppl 1():43-8. PubMed ID: 6343038
    [Abstract] [Full Text] [Related]

  • 34. [Treatment of type I diabetes mellitus with biosynthetic human insulin].
    Guagnano MT, Anichini M, Della Loggia F, Renzetti A, Vitacolonna E, Sensi S.
    Boll Soc Ital Biol Sper; 1985 Sep 30; 61(9):1267-72. PubMed ID: 3907668
    [No Abstract] [Full Text] [Related]

  • 35. Behaviour of insulin antibodies in diabetics treated with different insulins.
    Mincu I, Cheţa D, Ionescu-Tîrgovişte C, Mirodon Z, Sîntu E.
    Med Interne; 1980 Sep 30; 18(4):347-52. PubMed ID: 7006044
    [Abstract] [Full Text] [Related]

  • 36. [Antibodies against therapeutic animal insulins and homologous proteins in the course of diabetes in children and adolescents].
    Karczewska K.
    Med Dosw Mikrobiol; 1974 Sep 30; 26(4):317-24. PubMed ID: 4475335
    [No Abstract] [Full Text] [Related]

  • 37. Comparative trials with monocomponent (MC) and monospecies (MS) pork insulins in the treatment of diabetes mellitus. Influence on antibody levels, on insulin requirement and on some complications.
    Andreani D, Iavicoli M, Tamburrano G, Menzinger G, Maltarello C.
    Horm Metab Res; 1974 Nov 30; 6(6):447-54. PubMed ID: 4476720
    [No Abstract] [Full Text] [Related]

  • 38. Monocomponent insulin in maturity onset diabetes mellitus.
    Viswanathan M, Ramachandran A, Snehalatha C, Viswanathan M.
    J Indian Med Assoc; 1981 Mar 01; 76(5):73-5. PubMed ID: 7021694
    [No Abstract] [Full Text] [Related]

  • 39. Immunogenicity of semisynthetic human insulin.
    Rogala H, Lawecki J, Czyzyk A.
    Acta Med Pol; 1986 Mar 01; 27(1-2):45-50. PubMed ID: 3551505
    [No Abstract] [Full Text] [Related]

  • 40. [Our experience with monocomponent insulin therapy].
    Gerö L, Tamás G, Petrányi G, Korányi L, Baranyi E.
    Orv Hetil; 1977 May 15; 118(20):1165-7. PubMed ID: 854329
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.